AlphAIAlphAI — Financial news for AI agents
investing.com$OSCR

Oscar Health earnings beat by $0.63, revenue topped estimates

Oscar Health (NYSE: OSCR) reported Q3 EPS of $0.49, beating estimates by $0.63, with revenue of $5.14B, exceeding expectations. The company forecasts FY 2026 revenue of $19.00B-$19.30B. OSCR's stock is up 26.13% in the last 3 months and 112.50% year-over-year.

Original reporting
investing.com
Published Nov 5, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$OSCR
Bullish
high confidence
Mentioned
$OSCR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OSCRBullishHigh
01

Why it matters

The earnings surprise and raised guidance suggest near‑term upside, but investors should watch for any guidance revisions or cost concerns.

02

Market read

First‑report earnings beat for a mid‑cap health‑tech stock, offering a clear trading catalyst.

03

What to watch

Potential headwinds from regulatory changes or higher cost structure are not discussed.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Oscar Health is a U.S. health‑insurance technology company listed on NYSE. The article provides its Q3 earnings and guidance.

Company-level read

Ticker impact

$OSCRBullishHigh confidence
Context

Oscar Health reported Q3 EPS of $0.49, beating the estimate by $0.63 and revenue of $5.14B versus $4.69B consensus.

Expected impact

likely upward pressure as investors price in the earnings beat and raised FY revenue guidance.

Evidence & confidence

The surprise EPS beat and revenue beat are material new information; guidance is also above consensus, supporting a bullish short‑term move.

Market effects

Sector

Health‑tech insurers may see renewed interest as Oscar Health outperforms expectations.

Regional

U.S. market sentiment may improve slightly in the health‑tech segment.

Global

Limited to U.S. investors; no broader global macro effect.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit taking.

Key entities

  • company
    Oscar Health

    U.S. health‑insurance technology firm (NYSE: OSCR).

Read at source← All news

StoryOscar Health posts Q3 profit, lifts full‑year earnings and revenue outlook

Also covered by

3 outlets

Related articles

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

finance.yahoo.com
$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

fool.com
$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

247wallst.com